iBio, Inc. (IBIO) stock
IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30
$0.85+0.10 (+13.37%)
Close on Nov 18, 2026Market cap $54.54MP/E –Yield –
iBio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
iBio's operating income for the twelve months ending Sep 30, 2026 was -$37.53M. For fiscal 2026 it was -$35.14M. The highest annual figure on record is -$3.84M in fiscal 2014.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$35.14M | – |
| FY2025 | Jun 30, 2025 | -$18.60M | – |
| FY2024 | Jun 30, 2024 | -$16.63M | – |
| FY2023 | Jun 30, 2023 | -$29.34M | – |
| FY2022 | Jun 30, 2022 | -$29.70M | – |
| FY2021 | Jun 30, 2021 | -$31.11M | – |
| FY2020 | Jun 30, 2020 | -$14.00M | – |
| FY2019 | Jun 30, 2019 | -$15.79M | – |
| FY2018 | Jun 30, 2018 | -$14.23M | – |
| FY2017 | Jun 30, 2017 | -$14.27M | – |
| FY2016 | Jun 30, 2016 | -$9.89M | – |
| FY2015 | Jun 30, 2015 | -$6.67M | – |
| FY2014 | Jun 30, 2014 | -$3.84M | – |
| FY2013 | Jun 30, 2013 | -$6.67M | – |
| FY2012 | Jun 30, 2012 | -$9.33M | – |
| FY2011 | Jun 30, 2011 | -$9.65M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | -$8.34M | – |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | -$11.38M | – |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -$8.37M | – |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | -$9.45M | – |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | -$5.95M | – |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | -$5.20M | – |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | -$4.88M | – |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | -$4.42M | – |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -$4.11M | – |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -$3.41M | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$3.63M | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$4.50M | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$5.10M | – |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -$4.97M | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -$6.17M | – |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$10.57M | – |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -$7.64M | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$10.45M | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$6.79M | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -$9.44M | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$7.20M | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$7.55M | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -$6.92M | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -$2.93M | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$4.06M | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -$3.16M | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -$3.86M | – |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | -$4.05M | – |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | -$3.77M | – |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | -$4.02M | – |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | -$3.95M | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | -$3.95M | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -$3.49M | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -$3.43M | – |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | -$3.36M | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | -$3.86M | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | -$3.94M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | -$3.33M | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | -$3.15M | – |
See a number that looks wrong?